Valuation: ImmunoCellular Therapeutics Ltd

Market Cap 92.85M 79.53M 74.05M 68.26M 128M 8.89B 130M 876M 343M 4.45B 349M 341M 14.69B P/E 2020 *
-
P/E 2021 -3.82x
Enterprise Value 94.18M 80.67M 75.11M 69.24M 130M 9.02B 132M 889M 348M 4.52B 354M 346M 14.9B EV / Sales 2020 *
-
EV / Sales 2021 -
Free-Float
-
Yield 2020 *
-
Yield 2021 -

Financials

2020 2021
Net sales - -
Net income -1.94M -1.66M -1.55M -1.42M -2.67M -185M -2.72M -18.28M -7.16M -92.9M -7.27M -7.11M -306M -5.15M -4.41M -4.11M -3.79M -7.11M -493M -7.23M -48.58M -19.02M -247M -19.33M -18.91M -815M
Net Debt -263K -225K -210K -193K -363K -25.18M -369K -2.48M -971K -12.61M -987K -966K -41.6M 1.33M 1.14M 1.06M 978K 1.84M 127M 1.87M 12.55M 4.91M 63.78M 4.99M 4.89M 210M
Logo ImmunoCellular Therapeutics Ltd
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.
Employees
-
Sector
-